Evidence map›Paper›PMID 37293340›Full record

ArticleRadiology. Artificial intelligence2023

Impact of Different Mammography Systems on Artificial Intelligence Performance in Breast Cancer Screening.

Clarisse F de Vries, Samantha J Colosimo, Roger T Staff, Jaroslaw A Dymiter, Joseph Yearsley, Deirdre Dinneen, Moragh Boyle, David J Harrison, Lesley A Anderson, Gerald Lip and 1 more

Abstract read
In one paragraph

Article in Radiology. Artificial intelligence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Clarisse F de VriesFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).ORCID 0000-0002-9616-4231
Samantha J ColosimoFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Roger T StaffFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Jaroslaw A DymiterFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Joseph YearsleyFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Deirdre DinneenFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Moragh BoyleFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).ORCID 0000-0003-1947-7995
David J HarrisonFrom the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Lesley A Anderson *From the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).
Gerald Lip *From the Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (C.F.d.V., M.B., L.A.A.), School of Medicine, Medical Science and Nutrition (S.J.C., R.T.S.), and Grampian Data Safe Haven (DaSH), Aberdeen Centre for Health Data Science, Institute of Applied Health Sciences (J.A.D.), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB24 3FX, Scotland; National Health Service Grampian (NHSG), Aberdeen Royal Infirmary, Aberdeen, Scotland (S.J.C., R.T.S., G.L.); Kheiron Medical Technologies, London, England (J.Y., D.D.); and School of Medicine, University of St Andrews, St Andrews, Scotland (D.J.H.).ORCID 0000-0002-7867-5468
iCAIRD Radiology Collaboration

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) tools may assist breast screening mammography programs, but limited evidence supports their generalizability to new settings. This retrospective study used a 3-year dataset (April 1, 2016-March 31, 2019) from a U.K. regional screening program. The performance of a commercially available breast screening AI algorithm was assessed with a prespecified and site-specific decision threshold to evaluate whether its performance was transferable to a new clinical site. The dataset consisted of women (aged approximately 50-70 years) who attended routine screening, excluding self-referrals, those with complex physical requirements, those who had undergone a previous mastectomy, and those who underwent screening that had technical recalls or did not have the four standard image views. In total, 55 916 screening attendees (mean age, 60 years ± 6 [SD]) met the inclusion criteria. The prespecified threshold resulted in high recall rates (48.3%, 21 929 of 45 444), which reduced to 13.0% (5896 of 45 444) following threshold calibration, closer to the observed service level (5.0%, 2774 of 55 916). Recall rates also increased approximately threefold following a software upgrade on the mammography equipment, requiring per-software version thresholds. Using software-specific thresholds, the AI algorithm would have recalled 277 of 303 (91.4%) screen-detected cancers and 47 of 138 (34.1%) interval cancers. AI performance and thresholds should be validated for new clinical settings before deployment, while quality assurance systems should monitor AI performance for consistency.

Indexed as

BreastComputer Applications–Detection/DiagnosisMammographyNeoplasms-PrimaryScreeningTechnology Assessment

Identifiers

PMID37293340
PMCPMC10245180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.